Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

20250 citationsJournal Articlehybrid Open Access

Authors

Dan Turner · Shaare Zedek Medical Center

Kathleen G Lomax · Johnson & Johnson (United States)

Gigi Veereman · Universitair Ziekenhuis Brussel

AM Griffiths · Hospital for Sick Children

Jaroslaw Kierkuś · Children's Memorial Health Institute

Ben Kang · Kyungpook National University Hospital

Katherine Berezny ·

Abstract

Overall, the results of the PURSUIT 2 study support golimumab treatment for children with moderately-to-severely active UC. ClinicalTrials.gov ID: NCT03596645.

Topics & Keywords

Inflammatory Bowel Disease Rheumatoid Arthritis Research and Therapies Natural Compounds in Disease Treatment

Publication Details

Published in: Inflammatory Bowel Diseases

DOI: 10.1093/ibd/izaf322

Field-Weighted Citation Impact: 0.00

Command Palette

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Authors

Abstract

Topics & Keywords

Publication Details